| Stock Name | 盛禾生物－Ｂ |
|---|---|
| Stock Code | 02898 |
| Company Full Name | 盛禾生物－Ｂ |
| Industry | 醫療保健 |
| Principal Activities | 公司是一家生物制藥公司，致力于發現、開發和商業化生物制劑，通過直接調節先天和適應性免疫系統來調節免疫微環境，目前擁有三種核心產品，即IAH0968、IAP0971及IAE0972，均為自主研發。 |
| Listing Date | 2024-05-24 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國江蘇省南京市南京經濟技術開發區興建路5號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.sunho-bio.com.cn/ |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 13.50 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | No |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 9.1% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 46,105,200 |
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
| First Day Close | HK$ 14.52 |
|---|---|
| First Day Open | HK$ 14.46 |
| First Day Change | 7.56% |
| First Day Volume | 2768400.0 |
| First Day Turnover | 41081400.0 |
| Use of Proceeds | 1、28.2%或約110.4百萬港元將用于IAH0968在中國正在進行及計劃進行的臨床試驗； 2、35.8%或約140.1百萬港元將用于IAP0971在中國正在進行及計劃進行的臨床試驗； 3、36.0%或約141.1百萬港元將用于IAE0972在中國正在進行及計劃進行的臨床試驗。 |
|---|
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 南京经开未来科技产业投资合伙企业(有限合伙) | 41,798,700 HKD | — | 9.07% | — | 6 months | 2024-11-24 |
| Chairman | 張峰 |
|---|---|
| Company Secretary | 徐春芹;黃凱婷 |
| Major Shareholders & Holdings | Sunho Wisdom Investments Limited(56.17%);湖州市倚鋒安盛創業投資合伙企業(有限合伙)(7.45%) |
|---|
Market Sentiment
The public offer was oversubscribed by 10.08 times, indicating moderate enthusiasm. The hit rate of 39.22% is relatively high, reflecting that the allocation was not excessively competitive. Reallocation from the international tranche suggests that institutional demand was softer, making more shares available to retail investors. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Tier Analysis
No tier distribution data was provided, making it impossible to analyze 甲尾/乙头 inefficiencies or broker fee dynamics. Investors should refer to the official allocation results for detailed tier-level statistics. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
Demographics
Demographic data for this IPO was not available in the provided dataset. Typically, Hong Kong IPO filings include breakdowns of applicant regions and identity types, but they were missing here. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)
